"Methylphenidate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
| Descriptor ID |
D008774
|
| MeSH Number(s) |
D02.241.223.601.600 D03.383.621.460
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Methylphenidate".
Below are MeSH descriptors whose meaning is more specific than "Methylphenidate".
This graph shows the total number of publications written about "Methylphenidate" by people in this website by year, and whether "Methylphenidate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 6 | 0 | 6 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 5 | 2 | 7 |
| 2007 | 1 | 1 | 2 |
| 2008 | 6 | 0 | 6 |
| 2009 | 5 | 2 | 7 |
| 2010 | 5 | 0 | 5 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methylphenidate" by people in Profiles.
-
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379.
-
Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179.
-
Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial. Neuropsychopharmacology. 2017 Aug; 42(9):1766-1775.
-
LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study. Genes Brain Behav. 2015 Jun; 14(5):419-27.
-
Variability of kinematic graphomotor fluency in adults with ADHD. Hum Mov Sci. 2014 Dec; 38:331-42.
-
Dopamine and norepinephrine receptors participate in methylphenidate enhancement of in vivo hippocampal synaptic plasticity. Neuropharmacology. 2015 Mar; 90:23-32.
-
Survivorship: cognitive function, version 1.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):976-86.
-
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013 Jul 01; 31(19):2421-7.
-
Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. 2013 Oct; 13(5):476-80.
-
Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer. J Pediatr Psychol. 2011 May; 36(4):438-50.